-
平臺(tái)編號(hào)：bio-68265
-
國(guó)際編號(hào)：CRL-2656?
-
細(xì)胞信息： 310-29F7
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
310-29F7
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
數(shù)量：大量
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 and IgG2b
ATCC Number：CRL-2656?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：1mg Designations: 310-29F7
Depositors: ?National Cancer Institute
Isotype: IgG1 and IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a synthetic abl oncogene peptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic polypeptide with the sequence LGGGQYGEVYEG(C) corresponding to peptides 248 to 259 of the abl oncogene (formerly 368 to 379 of the v-abl oncogene).
Spleen cells were fused with Sp2/0 myeloma cells.
The monoclonal antibody does not cross react with the homologous regions of src, yes, mos, fes, mil, raf, fms, fgr, erb B, neu, HER, HIR, CDC28, or the catalytic or the regulatory subunit of bovine cyclic AMP dependent protein kinase in indirect ELISA.
The antibody does detect a 120 kd protein in ANN-1 cells when tested in an immunoblot test.
The IgG1 and IgG2b reactivities of the antibody with the ABL peptide (248 to 259) was confirmed by ELISA. IgG1 was strongly positive while IgG2b was only slightly positive.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
數(shù)量：大量
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 and IgG2b
ATCC Number：CRL-2656?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：1mg Designations: 310-29F7
Depositors: ?National Cancer Institute
Isotype: IgG1 and IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a synthetic abl oncogene peptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic polypeptide with the sequence LGGGQYGEVYEG(C) corresponding to peptides 248 to 259 of the abl oncogene (formerly 368 to 379 of the v-abl oncogene).
Spleen cells were fused with Sp2/0 myeloma cells.
The monoclonal antibody does not cross react with the homologous regions of src, yes, mos, fes, mil, raf, fms, fgr, erb B, neu, HER, HIR, CDC28, or the catalytic or the regulatory subunit of bovine cyclic AMP dependent protein kinase in indirect ELISA.
The antibody does detect a 120 kd protein in ANN-1 cells when tested in an immunoblot test.
The IgG1 and IgG2b reactivities of the antibody with the ABL peptide (248 to 259) was confirmed by ELISA. IgG1 was strongly positive while IgG2b was only slightly positive.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
